Scholarlink

Objective <p>To characterize patients with autoantibodies against metabotropic glutamate receptor 8 (mGluR8) and assess the pathogenicity of these antibodies.</p> Methods <p>Anti-mGluR8 antibodies were detected via cell-based assay and immunoprecipitation. Clinical data from five anti-mGluR8-positive patients and previously reported cases with other anti-mGluR antibodies were reviewed. Patient-derived IgG was purified and absorbed using mGluR8-expressing or control HEK293T cells. Pathogenicity was tested in hippocampal neuron cultures and via passive transfer into mice, with ataxia evaluated using behavioral tests.</p> Results <p>Five patients (4 male, median age 61) presented with subacute ataxia; other symptoms included dysarthria, ophthalmoplegia, dysphagia, and cognitive changes. Brain MRI showed cerebellar and cortical atrophy in all cases. Immunotherapy led to transient improvement in all patients, with stabilization in three of four with follow-up. In vitro, non-mGluR8-absorbed IgG reduced synaptic mGluR8 clusters. Mice injected with non-mGluR8-absorbed IgG developed transient ataxia peaking at 3–6&#xa0;h and resolving within 24&#xa0;h, correlating with antibody binding to Purkinje cells.</p> Conclusion <p>Anti-mGluR8 antibody is a novel possible biomarker for autoimmune ataxia, with its pathogenicity supported by passive transfer models.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neuronal antibody targeting metabotropic glutamate receptor 8 in five cases and its pathogenicity

  • 期刊论文

  • 发表日期：

    2026年2月10日

查看全文
  • Pei-Hao Lin,
  • Shi-Feng Zhang,
  • Hai-Yan Yao,
  • Wen-Dong Lai,
  • Shi-yu He,
  • Shi-chun Li,
  • Hui-Lu Li,
  • Zhan-Hang Wang,
  • Dong-Fang Cao,
  • Jie Yang,
  • Li Huang,
  • Ting Li,
  • Cong Gao,
  • Cong-Cong Fu,
  • An-lin Cai,
  • Li Ma,
  • You-Ming Long

摘要

Objective

To characterize patients with autoantibodies against metabotropic glutamate receptor 8 (mGluR8) and assess the pathogenicity of these antibodies.

Methods

Anti-mGluR8 antibodies were detected via cell-based assay and immunoprecipitation. Clinical data from five anti-mGluR8-positive patients and previously reported cases with other anti-mGluR antibodies were reviewed. Patient-derived IgG was purified and absorbed using mGluR8-expressing or control HEK293T cells. Pathogenicity was tested in hippocampal neuron cultures and via passive transfer into mice, with ataxia evaluated using behavioral tests.

Results

Five patients (4 male, median age 61) presented with subacute ataxia; other symptoms included dysarthria, ophthalmoplegia, dysphagia, and cognitive changes. Brain MRI showed cerebellar and cortical atrophy in all cases. Immunotherapy led to transient improvement in all patients, with stabilization in three of four with follow-up. In vitro, non-mGluR8-absorbed IgG reduced synaptic mGluR8 clusters. Mice injected with non-mGluR8-absorbed IgG developed transient ataxia peaking at 3–6 h and resolving within 24 h, correlating with antibody binding to Purkinje cells.

Conclusion

Anti-mGluR8 antibody is a novel possible biomarker for autoimmune ataxia, with its pathogenicity supported by passive transfer models.